Effects of lysophospholipids on tumor microenvironment

Cancer Microenvironment

Volumn 4, Issue 3, 2011, Pages 393-403

  Rolin, Johannes ^a   Maghazachi, Azzam A ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer; Lysophosphatidic acid; Lysophospholipids; Sphingosine 1 phosphate

Indexed keywords

CYCLOOXYGENASE 1; FINGOLIMOD; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; SPHINGOSINE 1 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; BRAIN CANCER; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CYTOLYSIS; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84856412755     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0088-1     Document Type: Review

References (115)

1. Chun J, Goetzl EJ, Hla T et al (2008) International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54:265-269
2. Rivera R, Chun J (2008) Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 160:25-46
3. Choi JW, Herr DR, Noguchi K et al (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157-186
4. Maghazachi AA (2005) Insights into seven and single transmembrane- spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol Rev 57:339-357 (Pubitemid 41196954)
5. Cinque B, Di ML, Centi C et al (2003) Sphingolipids and the immune system. Pharmacol Res 47:421-437 (Pubitemid 36379204)
6. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591 (Pubitemid 37328830)
7. Tigyi G, Dyer DL, Miledi R (1994) Lysophosphatidic acid possesses dual action in cell proliferation. Proc Natl Acad Sci USA 91:1908-1912 (Pubitemid 24080315)
8. Sengupta S, Xiao YJ, Xu Y (2003) A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 17:1570-1572
9. Sengupta S, Kim KS, Berk MP et al (2007) Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26:2894-2901 (Pubitemid 46701441)
10. Kim KS, Sengupta S, Berk M et al (2006) Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66:7983-7990 (Pubitemid 44299162)
11. Xu Y, Shen Z, Wiper DWet al (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723 (Pubitemid 28405297)
12. Sedláková I, Vávrová J, Tošner J, Hanousek L (2010) Lysophosphatidic acid in patients with ovarian cancer. Clin Ovarian Cancer 3:41-46
13. Masuda A, Nakamura K, Izutsu K et al (2008) Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 143:60-70
14. Sano T, Baker D, Virag T, Wada A et al (2002) Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 277:21197-21206 (Pubitemid 34952255)
15. Yatomi Y, Ohmori T, Rile G et al (2009) Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96:3431-3438
16. Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y (2001) Sphingosine 1-phosphate: synthesis and release. Prostaglandins 64:107-122 (Pubitemid 32452285)
17. Yang L, Yatomi Y, Miura Y et al (1999) Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol 107:282-293 (Pubitemid 29530212)
18. Kim RH, Takabe K, Milstien S, Spiegel S (2009) Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 1791:692-696
19. Xu Y, Fang XJ, Casey G, Mills GB (1995) Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309:933-940
20. Spiegel S, Milstien S (2004) Sphingosine-1-phosphate: signaling inside and out. FEBS Lett 476:55-57 (Pubitemid 30394650)
21. Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat Rev Immunol 8:753-763
22. Pyne S, Pyne NJ (2000) Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349:385-402 (Pubitemid 30465772)
23. Okazaki T, Bell RM, Hannun YA (1989) Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 264:19076-19080 (Pubitemid 19285812)
24. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139-150 (Pubitemid 351158911)
25. Mechtcheriakova D, Wlachos A, Sobanov J et al (2007) Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19:748-760 (Pubitemid 46275367)
26. Peest U, Sensken SC, Andreani P et al (2008) S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 104:756-772 (Pubitemid 351830827)
27. Zhao Y, Kalari SK, Usatyuk PV et al (2007) Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1. J Biol Chem 282:14165-14177 (Pubitemid 47100473)
28. Schwab SR, Pereira JP, Matloubian M et al (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735-1739 (Pubitemid 41285945)
29. Venkataraman K, Lee YM, Michaud J et al (2008) Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 102:669-676 (Pubitemid 351457860)
30. Pappu R, Schwab SR, Cornelissen I et al (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316:295-298 (Pubitemid 46633109)
31. Hanel P, Andreani P, Graler MH (2007) Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 21:1202-1209 (Pubitemid 46495709)
32. Hla T (2004) Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15:513-520 (Pubitemid 38953947)
33. Taha TA, Hannun YA, Obeid LM (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39:113-131
34. Goetzl EJ, Kong Y, Mei B (1999) Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162:2049-2056 (Pubitemid 29288824)
35. Xia P, Gamble JR, Wang L et al (2000) An oncogenic role of sphingosine kinase. Curr Biol 10:1527-1530 (Pubitemid 32003646)
36. Taha TA, Kitatani K, El-Alwani M et al (2006) Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J 20:482-484 (Pubitemid 46671223)
37. Kawamori T, Osta W, Johnson KR et al (2006) Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20:386-388 (Pubitemid 46671180)
38. French KJ, Upson JJ, Keller SN et al (2006) Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318:596-603 (Pubitemid 44061234)
39. French KJ, Schrecengost RS, Lee BD et al (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63:5962-5969 (Pubitemid 37187498)
40. Sankala HM, Hait NC, Paugh SW et al (2007) Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 67:10466-10474 (Pubitemid 350070822)
41. Van Brocklyn JR, Jackson CA, Pearl DK et al (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64:695-705 (Pubitemid 41177111)
42. Van Brocklyn JR, Young N, Roof R (2003) Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett 199:53-60 (Pubitemid 37088138)
43. Yoshida Y, Nakada M, Sugimoto N et al (2010) Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer 126:2341-2352
44. Jaillard C, Harrison S, Stankoff B et al (2005) Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25:1459-1469 (Pubitemid 40250722)
45. Young N, Van Brocklyn JR (2007) Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res 313:1615-1627
46. Van Brocklyn JR, Letterle C, Snyder P, Prior T (2002) Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Lett 181:195-204 (Pubitemid 34518304)
47. Morris AJ, Panchatcharam M, Cheng HYet al (2009) Regulation of blood and vascular cell function by bioactive lysophospholipids. J Thrombosis and Haemostasis 7(Suppl):43
48. Lee OH, Kim YM, Lee YM et al (1999) Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264:743-750
49. Paik JH, Skoura A (2004) Chae SS et al Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 18:2392-2403 (Pubitemid 39304686)
50. Chae SS, Paik JH, Furneaux H, Hla T (2004) Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 114:1082-1089 (Pubitemid 39578697)
51. Kono M, Mi Y, Liu Y, Sasaki T et al (2004) The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 279:29367-29373 (Pubitemid 38915815)
52. Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115:84-105 (Pubitemid 46990553)
53. Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349 (Pubitemid 34303689)
54. LaMontagne K, Littlewood-Evans A, Schnell C et al (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221-231 (Pubitemid 43166028)
55. Theilmeier G, Schmidt C, Herrmann J et al (2006) High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114:1403-1409 (Pubitemid 44454560)
56. Visentin B, Vekich JA, Sibbald BJ et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225-238 (Pubitemid 43357948)
57. Yamaguchi H, Kitayama J, Takuwa N et al (2003) Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J 374:715-722 (Pubitemid 37163916)
58. Arikawa K, Takuwa N, Yamaguchi H et al (2003) Liganddependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 278:32841-32851 (Pubitemid 37055726)
59. Matloubian M, Lo CG, Cinamon G et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360 (Pubitemid 38133663)
60. Dorsam G, Graeler MH, Seroogy C et al (2003) Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J Immunol 171:3500-3507 (Pubitemid 37254552)
61. English D, Kovala AT, Welch Z et al (1999) Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8:627-634 (Pubitemid 30041245)
62. Kveberg L, Bryceson Y, Inngjerdingen M et al (2003) Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur J Immunol 32:1856-1864 (Pubitemid 34822815)
63. Annabi B, Lachambre MP, Plouffe K et al (2009) Modulation of invasive properties of CD133 (+) glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. Mol Carcinogenesis 48:910-919
64. Park KS, Kim MK, Lee HY et al (2007) S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. Biochem Biophys Res Commun 356:239-244 (Pubitemid 46413154)
65. Okamoto H, Takuwa N, Yokomizo T et al (2000) Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol 20:9247-9261 (Pubitemid 32246111)
66. Lin DA, Boyce JA (2006) Lysophospholipids as mediators of immunity. Adv Immunol 89:141-167
67. Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161:241-270
68. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH (2004) G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92:949-966 (Pubitemid 44264244)
69. Liu S, Umezu-Goto M, Murph M et al (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15:539-550
70. Li H, Wang D, Zhang H, Kirmani K et al (2009) Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 8:1692-1701
71. Hu YL, Tee MK, Goetzl EJ et al (2001) Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768 (Pubitemid 32514799)
72. Xu X, Prestwich GD (2010) Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116:1739-1750
73. Shin KJ, Kim YL, Lee S, Kim D et al (2009) Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J Cancer Res Clin Oncol 135:45-52
74. Zeng Y, Kakehi Y, Nouh MA et al (2009) Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate 69:283-292
75. Lin S, Wang D, Iyer S, Ghaleb AM et al (2009) The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 136:1711
76. Shida D, Kitayama J, Yamaguchi H et al (2003) Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63:1706-1711 (Pubitemid 36373664)
77. Fang X, Schummer M, Mao M et al (2002) Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257-264 (Pubitemid 34634137)
78. Goetzl EJ, Dolezalova H, Kong Y et al (1999) Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 59:5370-5375 (Pubitemid 29504007)
79. Ye X, Hama K, Contos JJ et al (2005) LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435:104-108 (Pubitemid 40655916)
80. van Meeteren LA, Ruurs P et al (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015-5022 (Pubitemid 43955815)
81. Yu S, Murph MM, Lu Y et al (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630-1642
82. Jeon ES, Heo SC, Lee IH et al (2010) Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 from human mesenchymal stem cells. Exp Mol Med 42:280-293
83. Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD (2010) Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 8:309-321
84. Lin CI, Chen CN, Huang MT et al (2008) Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation-and EGFR transactivationdependent mechanisms. Cell Signal 20:1804-1814
85. Boucharaba A, Guillet B, Menaa F et al (2009) Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res 18:173-184
86. Fang X, Yu S, Bast RC et al (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279:9653-9661 (Pubitemid 38296034)
87. Wang FQ, Ariztia EV, Boyd LR et al (2010) Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol 117:88-95
88. Degousee N, Stefanski E, Lindsay TF et al (2001) p38 MAPK regulates group IIa phospholipase A2 expression in interleukin-1beta -stimulated rat neonatal cardiomyocytes. J Biol Chem 276:43842-43849
89. Goetzl EJ, Graeler M, Huang MC, Shankar G (2002) Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer. ScientificWorld-Journal 2:324-338
90. Stam JC, Michiels F, van der Kammen RA et al (1998) Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J 17:4066-4074 (Pubitemid 28333990)
91. Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295-1301 (Pubitemid 350131168)
92. Graeler M, Goetzl EJ (2002) Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 16:1874-1878 (Pubitemid 35462606)
93. Chi H, Flavell RA (2005) Regulation of T cell trafficking and primary immune responses by sphingosine 1-phosphate receptor 1. J Immunol 174:2485-2488 (Pubitemid 40279659)
94. Morris MA, Gibb DR, Picard F et al (2005) Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur J Immunol 35:3570-3580 (Pubitemid 43025537)
95. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ (2007) Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol 28:102-107 (Pubitemid 46283694)
96. Allende ML, Dreier JL, Mandala S, Proia RL (2004) Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279:15396-15401 (Pubitemid 38618938)
97. Wei SH, Rosen H, Matheu MP et al (2005) Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 6:1228-1235 (Pubitemid 43045634)
98. Sanna MG, Wang SK, Gonzalez-Cabrera PJ et al (2006) Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2:434-441 (Pubitemid 44114922)
99. Sawicka E, Zuany-Amorim C, Manlius C et al (2003) Inhibition of Th1-and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 171:6206-6214 (Pubitemid 37467244)
100. Jin Y, Knudsen E, Wang L, Bryceson Y et al (2003) Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 101:4909-4915 (Pubitemid 36857753)
101. Wang L, Knudsen E, Jin Y, Gessani S, Maghazachi AA (2004) Lysophospholipids and chemokines activate distinct signal transduction pathways in T helper 1 and T helper 2 cells. Cell Signal 16:991-1000 (Pubitemid 38798050)
102. Wolf AM, Eller K, Zeiser R et al (2009) The sphingosine 1-phosphate agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 183:3751-3760
103. Idzko M, Panther E, Corinti S et al (2002) Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 16:625-627
104. Eigenbrod S, Derwand R, Jakl V et al (2006) Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells. Immunol Invest 35:149-165
105. Panther E, Idzko M, Corinti S et al (2002) The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol 169:4129-4135 (Pubitemid 35178182)
106. Oz-Arslan D, Ruscher W, Myrtek D et al (2006) IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. J Leukoc Biol 80:287-297 (Pubitemid 44835502)
107. Albertsson PA, Basse PH, Hokland M et al (2003) NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24:603-609 (Pubitemid 37338529)
108. Maghazachi AA, Al-Aoukaty A (1998) Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer. FASEB J 12:913-924 (Pubitemid 28359572)
109. Maghazachi AA (2010) Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 341:37-58
110. Lagadari M, Lehmann K, Ziemer M et al (2009) Sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells via Gs protein-mediated signalling. Int J Oncol 34:287-294
111. Rolin J, Sand KL, Knudsen E, Maghazachi AA (2010) FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother 59:575-586
112. Jin Y, Knudsen E, Wang L, Maghazachi AA (2003) Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization. Eur J Immunol 33:2083-2089 (Pubitemid 37010024)
113. Lagadari M, Truta-Feles K, Lehmann K et al (2009) Lysophosphatidic acid inhibits the cytotoxic activity of NK cells: involvement of Gs protein-mediated signaling. Int Immunol 21:667-677
114. Shankaran V, Ikeda H, Bruce AT et al (2001) IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1071-111
115. Sand KL, Knudsen E, Rolin J et al (2009) Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 66:1446-1456